Glenmark Pharmaceuticals Limited · NSE:GLENMARK
Glenmark Pharmaceuticals — Q3 FY25 Earnings Presentation
17 slides from Glenmark Pharmaceuticals's earnings presentation, Feb 14, 2025
Slide 1: Cover letter to stock exchanges
February 14, 2025 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 532296
Slide 2: Investor Presentation: Q3 FY25
Investor Presentation: Q3 FY25 14 February 2025
Slide 3: Disclaimer
Disclaimer This document has been prepared by Glenmark Pharmaceuticals Ltd. and the information, statements and analysis made in this document describing the Company’s or its affiliates’ objectives, projections and estimates are forward looking statements. Forward-looking statements are all statemen
Slide 4: Q3 FY25 Summary
Q3 FY25 Summary “We delivered strong and sustained growth this quarter, driven by robust performance across the regions. Our European business Consolidated • Consolidated Revenue of Rs. 33,876 Mn continued to perform well, while our branded markets Revenue • YoY growth of 35.1% demonstrated resilien
Slide 5: Consolidated Revenue – Q3 FY25
Consolidated Revenue – Q3 FY25 Second Quarter ended Third Quarter ended December 31 September 30 Rs Mn FY 2024-25 FY 2023-24 YoY Growth FY 2024-25 QoQ Growth India 10,637 2,658 300.2% 12,817 -17.0% North America 7,813 7,705 1.4% 7,405 5.5% Europe 7,297 6,357 14.8% 6,874 6.1% Rest of the World1 7,491
Slide 6: P&L Highlights
P&L Highlights Rs. Mn Q3 FY25 Q3 FY24 %YoY Q2 FY25 %QoQ 9M FY25 9M FY24 %YoY Revenues from Operations 33,876 25,067 35.1% 34,338 -1.3% 1,00,655 87,501 15.0% Gross Margin 23,033 14,744 23,637 68,011 53,323 Gross Margin (%) 68.0% 58.8% 68.8% 67.6% 60.9% EBITDA 6,002 -2,086 6,019 -0.3% 17,904 6,910 159
Slide 7: India
31.4 Q3 % FY25 India Revenue (Rs. million) YoY: 300% Sustained outperformance Glenmark now ranked 13th QoQ: -17% compared to IPM# in IPM 12,817 10,637 Key Highlights 2,658 Glenmark’s India formulation business recorded a growth of 9.6% in Q3 FY25 and 12.3% as per MAT December 2024, compared to the
Slide 8: North America
31.4 Q3 % FY25 North America Revenue (Rs. million) YoY: 1.4% 8 injectable products are Plan to launch Respiratory QoQ: 5.5% now commercial products from H1 FY26 7,813 7,705 7,405 Key Highlights Launched Travoprost Ophthalmic Solution USP, 0.004% and Lacosamide Oral Solution, 10 mg/mL Q3 FY25 Q3 FY
Slide 9: Europe
31.4 Q3 % FY25 Europe Revenue (Rs. million) YoY: 14.8% Sustained growth in the QoQ: 6.1% Now ranked 13th in the branded Respiratory generic market of Germany# 7,297 business across markets 6,874 6,357 Key Highlights Branded business in Glenmark’s European operations continued its trajectory Q3 FY2
Slide 10: Rest Of the World (ROW)
31.4 Q3 % FY25 Rest Of the World (ROW)1 Revenue (Rs. million) Reported growth impacted YoY: 3.0% due to the adverse currency RYALTRIS® continues to QoQ: 6.4% movements in some of the scale up across markets 7,491 7,271 7,041 key markets Key Highlights Russia: Secondary sales growth of 16.6%; conti
Slide 11: Creating Global Brands – RYALTRIS®
Creating Global Brands – RYALTRIS® As of December 2024, marketing applications for RYALTRIS® have been submitted in more than 90 countries across the world and the product has been commercialized in 43 markets. Further, it is expected to be launched in 12-15 additional markets over the next few qu
Slide 12: Creating Global Brands – ENVAFOLIMAB & WINLEVI®
Creating Global Brands – ENVAFOLIMAB & WINLEVI® ENVAFOLIMAB The Company announced the signing of a license agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd (Jiangsu Alphamab) and 3D Medicines (Beijing) Co., Ltd. (3DMed) for Envafolimab for India, Asia Pacific, Middle East and Africa, Ru
Slide 13: ICHNOS GLENMARK INNOVATION
ICHNOS GLENMARK INNOVATION TREAT: Trispecific Engagement by Antibodies based on the T cell receptor BEAT: Bispecific Engagement by Antibodies based on the T cell receptor 12 ©2023 Glenmark Pharmaceuticals Ltd. All Rights Reserved
Slide 14: ICHNOS GLENMARK INNOVATION – Partnered Assets in Immunology
ICHNOS GLENMARK INNOVATION PARTNERED ASSETS IN IMMUNOLOGY ISB 880 / ALM27134 (IL-1RAP ANTAGONIST) o IGI entered an exclusive global licensing agreement for ISB 880 in autoimmune diseases with Almirall in December 2021. Within the terms of the agreement, Almirall assumed full cost and responsibilit
Slide 15: ICHNOS GLENMARK INNOVATION – Multiple Myeloma Overview
ICHNOS GLENMARK INNOVATION MULTIPLE MYELOMA (MM) OVERVIEW Remains a devastating and often fatal disease, with no current cure available. Despite advancements in treatment, many patients continue to face poor outcomes, especially those with relapsed or refractory (r/r) disease. Market projected t
Slide 16: ISB 2001 Data Presentation at ASH2024
ICHNOS GLENMARK INNOVATION ISB 2001 DATA PRESENTATION AT ASH2024 Twenty heavily pre-treated patients with r/r MM were enrolled as of October 1, 2024. These patients had received a median of 6 prior lines of therapy. About half of patients (n=9) had received bispecific antibodies, with other prior
Slide 17: Thank You
G Glenmark Thank You
Glenmark Pharmaceuticals — Q3 FY25 Earnings Presentation on 6ix